– GERMANY, Berlin – NOXXON Pharma N.V. (EPA: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), today announced the appointment of Dr. Oscar Izeboud to its Supervisory Board at the annual general shareholders meeting held on Tuesday, June 30, 2020.
“We are very pleased to welcome Oscar to the NOXXON supervisory board. He brings both a deep understanding of medicine and extensive experience in the financing and business side of biotechnology. While leading life science & healthcare banking at Kempen and NIBC, Oscar successfully closed more than 100 transactions, including 17 IPOs and 15 mergers or acquisitions. This experience combined with his operational biotech background will be incredibly valuable to refine and implement NOXXON’s strategy,” said Board Chairman, Maurizio PetitBon.
About Dr Oscar Izeboud
Dr. Izeboud is CEO of Scenic Biotech, drug discovery and development company focused on genetic modifiers, based in the Netherlands. Before joining Scenic Biotech, Dr. Izeboud was Managing Director at NIBC Bank N.V. in Amsterdam, where he headed a life sciences and healthcare team and led corporate finance and capital markets activities with a focus on innovative companies. Prior to that, as Managing Director at Kempen & Co., a Dutch investment bank, he built the Life Sciences and Healthcare franchise and played a pivotal role in numerous international transactions in biotech, MedTech, and the healthcare industry. Before his transition to the banking sector, Dr. Izeboud’s initial interest was in the biotech industry where he spent a number of years working for Crucell NV, Specs BV, and TNO Pharma.
Dr. Izeboud has been a non-executive member of the board of directors of Luciole Medical AG since 2019. He holds a Ph.D. in immunopharmacology from the University of Utrecht in the Netherlands.
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor microenvironment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 has delivered top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients and further studies are being planned in these indications. In September 2019 the company initiated an additional trial with NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX‑E36 in patients with solid tumors both as a monotherapy and in combination.
More information at: www.noxxon.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.